Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05237882
Other study ID # FGID Single case
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date August 1, 2022
Est. completion date June 15, 2023

Study information

Verified date December 2023
Source Aarhus University Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Functional gastrointestinal disorders (FGID) are common among children and adolescents. They affect quality of life, cause functional disability, school absence and high health care use. Despite this there is a lack in treatment options. The aim of the current study, embedded in The Danish FGID Treatment Study, is to investigate the detailed course of efficacy of Danish versions of Swedish Internet based cognitive behavioural therapy (i-CBT) programs for children and adolescents with FGID in a Danish clinical context. This will be done using a single case design study. Along with this, the impact of parental illness worries will be investigated.


Description:

A non-concurrent multi-variate baseline single-case experimental design study (SCED) will be conducted. It will consist of a baseline phase, a treatment phase and a follow up phase, including 6 children and 6 adolescents with their parents. Participants will be randomly assigned to a baseline length with a duration between 5-15 days. The design, using a multi-variate baseline, enables each participant to form their own control as outcomes during the baseline are compared with outcomes during treatment. This means that if treatment is effectual a change in outcome measures will show during the treatment period no matter when the treatment period was started. Outcome will be assessed daily from baseline to end of treatment using electronic self-report questionnaire, with a last, one week long, daily assessment at 3-month follow-up. The questionnaire is designed for this specific study and consist of 8 items (modified to a daily question) from validated questionnaires, the scale is changed to an 11 point scale from 0(not at all) to 10(all the time) Outcome are: abdominal symptoms (2 items from PedsQL Gastro 9 items questionnaire), symptom catastrophizing (2 items from Visceral Short sensitivity Index questionnaire), avoidance and control behavior (2 items from IBS Behavioural Response Questionnaire), and symptom acceptance(2 items from Chronic Pain Acceptance Questionnaire for Adolescents 8-items) In addition, a more comprehensive battery of questionnaires will be completed by the children and adolescents and the parent, respectively, at baseline, mid-treatment, end of treatment and at 3-month follow-up.


Recruitment information / eligibility

Status Completed
Enrollment 12
Est. completion date June 15, 2023
Est. primary completion date June 15, 2023
Accepts healthy volunteers No
Gender All
Age group 8 Years to 17 Years
Eligibility Inclusion Criteria: - child age: 8-12 years, adolescents: 13 - 17 years - A primary diagnosis according to the ROME-IV criteria of one of the FGID sub-types: Irritable bowel syndrome (IBS) or functional abdominal pain not-otherwise-specified (FAP-NOS) - The diagnosis should be documented by their regular physician in the somatic setting, and recommended routine medical investigations should be evaluated as normal or without clinical significance (include growth; blood samples including TSH, total IgA, IgA tissue transglutaminase, complete blood count, C-reactive protein analysis, liver enzymes; and fecal calprotectin) - Stable dosage of FGID-related medication such as laxatives, anti-diarreal medication or pain-modulating psychopharmacological medication during the past month. Exclusion Criteria: - Another disease that explains the symptoms; - Severe psychiatric or social problems (e.g., high level of suicidal ideation or ongoing abuse); - Ongoing psychological treatment; - Insufficient language or computer skills (patients and parents); - Severe family problems (e.g. child abuse, parental substance abuse or severe psychiatric illness, ongoing custody fight) - School absence of more than 40% over the past month.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Internet delivered cognitive behavioural therapy for functional gastrointestinal disorders
The offered treatment will be the Danish versions of the Swedish i-CBT programs for children. The child i-CBT program consists of 10 modules for the child and 10 for parents. The adolescent i-CBT program consists of 10 modules for the adolescent and 5 modules for the parents. Child and adolescents modules compose of exposure exercises for symptoms, behavioural analyses and affect labelling and are adjusted for the specific age group. Parent modules aim at supporting parents in helping their child to engage in the challenging exposure exercises. The family needs to select one parent to participate in the parent program. The participants will be expected to use approximately 4 hours per week. The programs will be delivered over ten weeks, and therapist support will be provided on a weekly basis.

Locations

Country Name City State
Denmark Aarhus University and Aarhus University Hospital, Child and Adolescents Psychiatry Aarhus

Sponsors (2)

Lead Sponsor Collaborator
Aarhus University Hospital Karolinska Institutet

Country where clinical trial is conducted

Denmark, 

Outcome

Type Measure Description Time frame Safety issue
Other Treatment satisfaction by the self-report questionnaire Modified Experience of Service Questionnaire 10 items rated either true, partly true, not true or don't know and 3 open end questions about experience of treatment, At 10 weeks of treatment (End of treatment)
Other Adverse events Open end questions. Parents to children aged 8-12 years will answer on behalf of their children and adolescents aged 13-17 years will answer themselves. At 10 weeks of treatment (End of treatment)
Primary Single Case Design Outcome: Change in gastrointestinal symptoms measured via Daily Items as part of self-report SCED-Questionnaire The SCED-Questionnaire consists of 8 daily items about Gastrointestinal symptoms, catastrophizing, Avoidance and control, acceptance. Answered on a 11 point scale from 0 ("not at all") to 10 ("all the time") Everyday during baseline (5-15 days before treatment start) and treatment (10 weeks) and during one week at 3 months follow-up
Primary Change in gastrointestinal symptoms assessed by PedsQL Gastro Symptom Scales The self-report questionnaire revised version of PedsQL Gastro Symptom Scales, with 9 items. Answered on a 5 point scale from 0 ("never") to 4 ("almost always) At baseline, after 5 weeks of treatment (mid-treatment), after 10 weeks of treatment (end-treatment) and 3-months after treatment (follow-up)
Primary Change in gastrointestinal symptoms rated by parents assessed by PedsQL Gastro Symptom Scales The parent-report questionnaire revised version of PedsQL Gastro Symptom Scales, with 9 items. Answered on a 5 point scale from 0 ("never") to 4 ("almost always) At baseline, after 5 weeks of treatment (mid-treatment), after 10 weeks of treatment (end-treatment) and 3-months after treatment (follow-up)
Secondary Single Case Design Outcome: Change in catastrophizing, avoidance and control and acceptance via Daily Items, measured as part of self-report SCED-Questionnaire Measured as part of self-report SCED-Questionnaire of 8 daily items about Gastrointestinal symptoms, catastrophizing, Avoidance and control, acceptance. Answered on a 11 point scale from 0 ("not at all") to 10 ("all the time") Everyday during baseline (5-15 days before treatment start) and treatment (10 weeks) and during one week at 3 months follow-up
Secondary Changes in Quality of life assessed by the Pediatric Quality of Life Inventory The self-report questionnaire Pediatric Quality of Life Inventory 8-12-year version for children, 13-18-year version for adolescents. 23 items, Answered on a 5 point scale from 0 ("never") to 4 ("almost always) At baseline, after 5 weeks of treatment (mid-treatment), after 10 weeks of treatment (end-treatment) and 3-months after treatment (follow-up)
Secondary Changes in Quality of life rated by parents assessed by Pediatric Quality of Life Inventory The parent-report questionnaire Pediatric Quality of Life Inventory for parents, (Parent report for children aged 8-12 years, and parent report for adolescents aged 13-17 years) . 23 items, Answered on a 5 point scale from 0 ("never") to 4 ("almost always) At baseline, after 5 weeks of treatment (mid-treatment), after 10 weeks of treatment (end-treatment) and 3-months after treatment (follow-up)
Secondary Changes in Pain intensity measured by the self-report rating scale, Faces pain scale, revised The scale consists of 6 faces representing least to most pain, and each face is connected to a number from 0 (no pain) - 10 (most pain), At baseline, after 5 weeks of treatment (mid-treatment), after 10 weeks of treatment (end-treatment) and 3-months after treatment (follow-up)
Secondary Changes in Pain intensity rated by parents Measured by the parent-report rating scale, Faces pain scale, revised. The scale consists of 6 faces representing least to most pain, and each face is connected to a number from 0 (no pain) - 10 (most pain), At baseline, after 5 weeks of treatment (mid-treatment), after 10 weeks of treatment (end-treatment) and 3-months after treatment (follow-up)
Secondary Changes in Overall symptom load measured by the self-report questionnaire Children somatization inventory , short (CSI) The questionnaire consist of 24 items Answered on a 5 point scale from 0 ("not at all") to 4 ("a whole lot") At baseline, after 5 weeks of treatment (mid-treatment), after 10 weeks of treatment (end-treatment) and 3-months after treatment (follow-up)
Secondary Changes in Overall symptom load rated by parents measured by the parent-report questionnaire Children somatization inventory (parent report), short The questionnaire consists of 24 items Answered on a 5 point scale from 0 ("not at all") to 4 ("a whole lot") At baseline, after 5 weeks of treatment (mid-treatment), after 10 weeks of treatment (end-treatment) and 3-months after treatment (follow-up)
Secondary Changes in Depression symptoms measured by the self-report questionnaire Mood and Feelings Questionnaire short The questionnaire consists of 13 items, answered on a 3 point scale: not true / sometimes true / true At baseline, after 10 weeks of treatment (end-treatment) and 3-months after treatment (follow-up)
Secondary Changes in General Anxiety symptoms measured by the self- report questionnaire Spence Children Anxiety Scale short A 19 item-questionnaire answered on a 4 point scale from 0(never) to 3 (always) At baseline, after 10 weeks of treatment (end-treatment) and 3-months after treatment (follow-up)
Secondary Changes in General Anxiety rated by parents, Measured by the parent- report questionnaire Spence Children Anxiety Scale short, parent report a19 item-questionnaire answered on a 4 point scale from 0(never) to 3 (always) At baseline, after 10 weeks of treatment (end-treatment) and 3-months after treatment (follow-up)
Secondary Changes in Specific Gastrointestinal Anxiety, Measured by the self-report questionnaire Visceral Sensitivity Index - Short A 7 item-questionnaire answered on a 5 point scale from 0 (don't agree at all) to 5 (totally agree) At baseline, after 5 weeks of treatment (mid-treatment), after 10 weeks of treatment (end-treatment) and 3-months after treatment (follow-up)
Secondary Changes in Avoidance and control behaviour measured by the self-report questionnaire irritable bowel syndrome-behavioural response questionnaire A 11 item-questionnaire answered on a 7 point likert scale from 1(never) to 7(always) At baseline, mid-treatment, end-treatment and 3-months follow-up
Secondary Changes in Illness perception Measured by the self-report questionnaire Brief Illness perception Questionnaire A questionnaire with 11 items answered on a scale from 0 - 10 At baseline, after 5 weeks of treatment (mid-treatment), after 10 weeks of treatment (end-treatment) and 3-months after treatment (follow-up)
Secondary Changes in Illness perception rated by parents, measured by the parent-report questionnaire Illness perception regarding child's symptoms Questionnaire A questionnaire with 11 items answered on a scale from 0 - 10 At baseline, after 5 weeks of treatment (mid-treatment), after 10 weeks of treatment (end-treatment) and 3-months after treatment (follow-up)
Secondary Changes in Illness worry Measured by the self-report questionnaire Childhood Illness Attitude Scale The cognitive domain of the questionnaire is used, it consists of 11 items, answers: never, sometimes or always At baseline, after 5 weeks of treatment (mid-treatment), after 10 weeks of treatment (end-treatment) and 3-months after treatment (follow-up)
Secondary Changes in Acceptance, measured by the self-report questionnaire Chronic pain Acceptance Questionnaire -adolescents Two items from the self-report questionnaire Chronic pain Acceptance Questionnaire -adolescents are used. 2 selected items, answered on a 5-point scale from 0 (never true) to 4 (always true) At baseline, mid-treatment, end-treatment and 3-months follow-up
Secondary Changes in PARENTAL Illness Worry measured by the self-report The Health Anxiety by Proxy Scale (HAPYS) questionnaire Parental illness worry for their child, measured by the self-report The questionnaire covers 26 items about health anxiety by proxy, rated on a five-point scale (from "not at all"/"never" to "a whole lot"/"most of the time"). And five items about the impact of the worries rated on a four-point scale (from "no" to "yes, severely"). At baseline, after 5 weeks of treatment (mid-treatment), after 10 weeks of treatment (end-treatment) and 3-months after treatment (follow-up)
Secondary Changes in PARENTAL Emotional distress measured by the self-report questionnaire Symptom Check List (SCL-8) The questionnaire consist of 8 items answered on a 5 point scale from 0 (not at all) to 4 (a whole lot) At baseline, after 5 weeks of treatment (mid-treatment), after 10 weeks of treatment (end-treatment) and 3-months after treatment (follow-up)
Secondary Changes in Adult Response to Child's Symptoms - PARENTS by the self-report questionnaire Adult Response to Children's Symptoms Protect and Monitor scale from the the questionnaire Adult Response to Children's Symptoms used, 15 items answered on a 5 point scale from 0(never) to 4 (always) At baseline, after 5 weeks of treatment (mid-treatment), after 10 weeks of treatment (end-treatment) and 3-months after treatment (follow-up)
Secondary Changes in School absence / Work absence parent Question about Hours / Days missed from school/work last month. Parental rated for children aged 8-12 years, self-rated for adolescents aged 13-17 years, self-rated for parents At baseline, after 5 weeks of treatment (mid-treatment), after 10 weeks of treatment (end-treatment) and 3-months after treatment (follow-up)
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05936112 - Quantification of Fecal Calprotectin Concentration Difference Between Infants Aged Under 4 Months Old Suffering From Functional Gastrointestinal Disorders (FGID) and Infants Aged Under 4 Months Old Free From Disorders : a Transversal Case-control Monocentric Study N/A
Completed NCT02565355 - Targeted Food Elimination for Treatment of Functional Gastrointestinal Diseases in Children N/A
Completed NCT02657668 - Emotion Focused Therapy in Irritable Bowel Syndrome Patients N/A
Completed NCT02731664 - GLP-1 Inhibits Prandial Antro-duodeno-jejunal Motility in Humans Phase 1
Recruiting NCT06205446 - Application of Diaphragmatic Breathing in Patients With Disorders of Gut-brain Interaction N/A
Recruiting NCT05718960 - Traditional Dietary Advice Versus Reassurance-alone in Postprandial Functional Dyspepsia N/A
Terminated NCT04247100 - A Study of Randomized Sham-control Auricular TENS Unit Stimulation in Pediatric Functional Gastrointestinal Disorders N/A
Recruiting NCT03625674 - Impact of Stigma on Compliance to Medication in Functional Dyspepsia N/A
Completed NCT03252743 - ICBT for Pain-predominant FGIDs in Children and Adolescents: an Implementation Study. N/A
Recruiting NCT05832528 - Low FODMAP Diet in FD (PDS) N/A
Completed NCT02936713 - Effect of Controlled Diet Combined With a Fermented Milk Product on Gas-related Symptoms N/A
Terminated NCT01712412 - Phase 2a Study of IW-9179 to Treat Functional Dyspepsia Phase 2
Completed NCT00564525 - Study of Medication for Functional Abdominal Pain in Children Phase 4
Recruiting NCT05987813 - Transcutaneous Electric Nerve Stimulation (TENS) for Vagal Modulation N/A
Completed NCT04155801 - A Study to Assess the Efficacy and Safety of Salix Probiotic Blend in Participants With Functional Gastrointestinal Disturbances N/A
Recruiting NCT05880199 - BSGM to Evaluate Patients With GI Symptoms
Recruiting NCT04625881 - Effects of an Apple Derived Fibre Supplement on Constipation Phase 3
Completed NCT03608735 - Prevalence of Functional Gastrointestinal Disorders (FGIDs), Related Signs and Symptoms in Infants/Toddlers in Thailand
Recruiting NCT04773158 - Systematic Pediatric Assessment of Rome Criteria N/A
Completed NCT02306369 - Internet-delivered CBT for Irritable Bowel Syndrome in Adolescents N/A